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Clinical, legal and ethical implications of the intra-ocular 
(off-label) use of bevacizumab (Avastin) – a South African 
perspective
Rita-Marié Jansen, Chris Gouws
Clinical background
Bevacizumab (Avastin) is registered for the treatment of 
metastatic colorectal and breast cancer.  Avastin blocks vascular 
endothelial growth factor (VEGF) and was the first clinically 
available angiogenesis inhibitor in the USA. Blocking or 
inhibiting VEGF prevents further growth of blood vessels, thus 
impeding the tumour’s blood supply.1
Ophthalmologists are using intra-ocular (intravitreal) 
injections of Avastin to treat neurovascular age-related 
macular degeneration (AMD). Choroidal neovascularisation 
is a potentially visually devastating element of various forms 
of eye pathology. Research has focused on AMD as a cause 
and has attracted significant funding in Europe and the USA 
because of their ageing populations. 
AMD can be classified as exudative (wet) or atrophic (dry). 
Dry AMD is slowly progressive and rarely leads to total 
blindness. Wet AMD is characterised by a pathological process 
in which new blood vessels develop in the choroids,2 causing 
leakage of fluid and haemorrhage under the retina and leading 
to localised serous detachment and loss of central vision. AMD 
is the leading cause of blindness in people over 50 years of age. 
Wet AMD may initially be reversible, but without treatment 
permanent loss of vision may be quick and severe.3
Treatment options have until recently yielded disappointing 
results. Treatment with Argon laser can cause shrinkage 
and atrophy of the offending choroidal vessels, but with 
unacceptable collateral damage.4 Photodynamic therapy with 
verteporfirin only slows down disease progression. Surgery, 
involving removal of the sub-foveal neovascular complex 
or rotation of the whole or part of the retina to effectively 
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Choroidal neovascularisation is a potentially visually 
devastating element of various forms of eye pathology. Recent 
research has focused on neurovascular age-related macular 
degeneration (AMD) as a cause. AMD can be classified 
as being exudative (wet) or atrophic (dry). Wet AMD is 
characterised by a pathological process in which new blood 
vessels develop in the choroids, causing leakage of fluid and 
haemorrhage under the retina and leading to localised serous 
detachment and loss of central vision. Vascular endothelial 
growth factor (VEGF) stimulates growth of neovascular 
membranes. Treatments have until recently yielded 
disappointing results.
Ophthalmologists are using intra-ocular injections of 
bevacizumab (Avastin), an anti-VEGF, to treat AMD. Avastin 
appears to be safe and effective in the short term, but its intra-
ocular administration is entirely off-label. Avastin is registered 
for treating metastatic colorectal and breast cancer. 
The off-label use of medication is an important part 
of mainstream, legitimate medical practice worldwide. 
Lawyers representing plaintiffs injured by drugs increasingly 
encounter off-label use claims. From a legal/ethical point 
of view the off-label use of medication represents a delicate 
balance between the statutory regulation of medication and 
a physician’s prerogative to prescribe medication that in his 
or her medical opinion will be beneficial to the patient. The 
main reason for the controversy created by the off-label use of 
Avastin is that there are anti-VEGF drugs on the market that 
have formal approval for the treatment of AMD (and other 
eye conditions). Lucentis, for example, is extremely expensive, 
with treatment cost approximately 50 times that of Avastin. 
Many patients suffering from AMD and macular oedema 
cannot afford the registered product.
The off-label use of Avastin has passed the innovative 
or experimental stages, as ophthalmologists have used it 
regularly and openly for a long time, with good success. 
Such use therefore cannot be considered careless, imprudent 
or unprofessional. We submit that an ophthalmologist who 
omits to inform a patient of the availability of Avastin for this 
form of treatment may be found to be negligent. 
Protocols developed by the South African Vitreoretinal 
Society and endorsed by the Ophthalmological Society of 
South Africa for administering Avastin and other intra-ocular 
medication intravitreally should be strictly adhered to.
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translocate the macula, has had disappointing results and 
significant complications.5
Enter the anti-VEGFs. VEGF stimulates growth of 
neovascular membranes. The intravitreal injection of anti-
VEGF antibodies reduces the amount of VEGF and interrupts 
the pathological process.
Intra-ocular administration of bevacizumab (Avastin) is 
entirely off-label. It is formulated for intravenous infusion, not 
intravitreal injection, and the Food and Drug Administration 
(FDA) approved its use for colon cancer in February 2004. In 
2005 Philip Rosenfeld first injected Avastin into a human eye 
and two case reports showed benefit; the first patient had 
neovascular AMD and the second had central retinal vein 
occlusion. After this its intra-ocular use spread rapidly around 
the world.6
However, there is no long-term safety and efficacy 
information for intravitreal bevacizumab based on large 
randomised trials and no true dose escalating/ranging studies. 
There is therefore no scientifically determined optimal dose 
and dose frequency,1 but bevacizumab appears to be safe 
and effective in the short term.6-9 Besides, ophthalmologists 
frequently use medications off-label. Intra-ocular triamcinolone 
is a typical example.
Pegaptanib (Macugen) and ranibizumab (Lucentis) were two 
anti-VEGF contenders in the race to get a registered drug on 
the market via the obstacles of the FDA. 
Legal implications of the off-label use 
of medication
‘Off-label’ means that the medicine is used in another way or 
for an indication other than those specified in the conditions 
of its registration and reflected in its labelling.10 This does 
not necessarily imply that the medication is not effective 
or is unsafe to be used in this way.11 Off-label use is an 
important part of mainstream, legitimate medical practice and 
is a worldwide phenomenon.12  According to the American 
Medical Association, 40 - 60% of all prescriptions in the USA 
are off-label. The off-label use of medication is common 
practice, especially in oncology, obstetrics, paediatrics, 
infectious diseases (notably HIV) and rare diseases.13 Lawyers 
representing plaintiffs injured by drugs increasingly encounter 
off-label use claims.14 Off-label use of medication can vary from 
being experimental or controversial to standard practice and 
even state-of-the-art treatment.12
When will off-label use of medication be negligent 
and when not?
From a legal/ethical point of view the off-label use of 
medication represents a delicate balance between the statutory 
regulation of medication (to safeguard patients) and the 
physician’s prerogative to prescribe medication that in his or 
her medical opinion will benefit the patient.15  This freedom 
to prescribe is not unsupervised; fear of delictual liability and 
medical malpractice claims are a check on the prescribing of 
physicians, who must balance the benefits against the risks.11
Physicians learn about off-label uses of medication through 
professional medical literature, presentations and peer lectures 
at conferences, medical research and advice from colleagues.  
They cannot prescribe or administer medication off-label with 
the same confidence as with registered medication. Information 
regarding possible side-effects, correct dosage and route of 
administration is normally unavailable, and anecdotal evidence 
is not the equivalent of clinical tests.15 Side-effects occur more 
often where medication is used off-label.16
Prescribing or administering medication off-label is 
acceptable medical practice when done by an informed, 
competent and experienced physician. Reasonable and 
acceptable medical practice was described as follows:17 ‘In 
deciding what is reasonable the court will have regard to the 
general level of skill and diligence possessed and exercised 
at the time by the members of the branch of the profession to 
which the practitioner belongs.’
A patient may successfully sue the practitioner if it 
can be proved that the off-label use of the medication in 
the circumstances was negligent, namely that harm was 
reasonably foreseeable and preventable. If off-label use of the 
specific medication has taken place regularly and openly and 
colleagues have also been doing it, over a period of time, with 
a reasonable degree of success and without patients being 
harmed, it would be almost impossible for a prospective 
patient to establish that harm was reasonably foreseeable.10 
‘Physicians may be found negligent if their decision to 
use a drug off-label is sufficiently careless, imprudent or 
unprofessional.’18
In a law-suit the defendant doctor is required to provide 
sound scientific evidence, from medical literature and expert 
evidence, that the off-label use is acceptable, effective and 
without known harmful side-effects. Strong scientific evidence 
for the safe use of off-label uses of medication exists in only 
28% of cases; in 72% there is little or no scientific evidence.19 
The risk of liability is heightened when the medical practitioner 
relies exclusively on his own experience and the experience 
of his or her colleagues. These cases often end up as a battle 
of experts. Experts for the plaintiff will try to prove that the 
defendant’s conduct deviated grossly from the standard 
practice set out in the labelling. Experts for the defendant 
doctor will try to demonstrate conduct in accordance with 
what other doctors are doing and therefore in accordance with 
ordinary protocol.14 In Durr v. ABSA Bank Ltd20 the Supreme 
Court of Appeal emphasised that although the court will pay 
much attention to the views of the profession, it is not bound 
to adopt them. The court must ultimately decide what is 
reasonable in the circumstances.
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The court will take the package insert and other information, 
such as that in the South African Medicines Formulary, into 
consideration when determining the proper use of the 
medication. There is no case law in South Africa where a 
finding on the evidentiary value of the package insert and 
other labelling was made. We submit that because medical 
discovery runs ahead of the Medicines Control Council 
(MCC)’s registration process, the labelling should not per se 
be regarded as an indication of standard practice. As in most 
judgments in the USA18 it should, however, be an important 
factor to take into account.
Where off-label use is the standard of care, failure to follow 
this standard may be grounds for malpractice claims.11
It is highly recommended that medical practitioners keep a 
separate file of the latest professional information and medical 
literature regarding the off-label use of medication.
Must the patient be informed that the medication is 
used off-label? 
The doctrine of informed consent requires the medical 
practitioner to give a patient the material information regarding 
the proposed treatment, alternatives, potential risks and 
benefits of each potential treatment, and the result of no 
treatment. Most judgments in the USA21 view that use of 
medication off-label pertains to the regulatory status of the 
medication only and is not relevant medical information that 
must be disclosed to the patient, but this remains a contentious 
topic.
The opposing argument is that off-label use lacks the 
assurances of safety and efficacy that an approved indication 
has, which is important information the reasonable patient 
would want to know before making a decision.15 Because there 
is no case law on this in South Africa the court may hold that 
a finding of lack of informed consent cannot be based solely 
on the off-label status of the medication not being revealed. 
Circumstances may also play a deciding role: if a medication is 
prescribed at a higher than approved dose, and it is standard 
practice to do so, it will be difficult to convince the court 
that this was material information. However, this will differ 
when the medication is used for a different condition and in 
a different manner to that approved, even if it is regarded 
as standard practice to do so, e.g. the intravitreal injection of 
a medication to treat AMD that was approved to be given 
intravenously for the treatment of metastatic cancer of the 
colon. 
Generally speaking it would be good medical practice 
to reveal the off-label use of medication.  If not revealed it 
could, for instance, confuse the patient should he or she read 
the package insert.  This information can also be important 
to determine whether the medical aid fund will pay for the 
treatment. To safeguard against possible litigation it is highly 
recommended that practitioners should discuss the off-label 
use of medication with their patients and document the 
discussion.  Informed consent is imperative if there is little 
research or other evidence of current practice, or if the use of 
the medicine in this way is innovative.
The ‘off-label’ use of bevacizumab 
(Avastin)
The ‘off-label’ use of bevacizumab (Avastin) for medical, retinal 
and vitreo-retinal treatment has been controversial mainly 
because two anti-VEGF drugs are on the market, specifically 
developed and with formal approval (e.g. USA, Switzerland 
and South Africa) for treating AMD (and other eye conditions), 
namely ranibizumab (Lucentis) and pegaptanib (Macugen). 
Genentech developed bevacizumab (Avastin) and 
ranibizumab (Lucentis), and because of lack of economic 
incentive has little interest in getting Avastin registered for 
ophthalmic use. Bevacizumab is derived from the same mouse 
monoclonal antibody precursor as ranibizumab. It neutralises 
VEGF when injected into the eye at a dose of 1.25 mg, normally 
in 0.05 ml.6 The company has explained its position on the use 
of intra-ocular Avastin: ‘We have a huge database suggesting 
that Lucentis is very effective and very safe, so we are just not 
sure of the value of taking something that is not formulated 
for the eye and subjecting patients to a randomized trial when 
there is, in our opinion, a very low likelihood of it being 
superior ...’, but acknowledged: ‘If people have a hypothesis 
that it would be better or safer, one could certainly test that.’6  
Ranibizumab was developed after bevacizumab and is a 
small portion of the bevacizumab molecule, which has helped 
to lower the overall risks such as arterial thrombo-embolic 
events.1,6  
However, the cost of treatment with Lucentis is 
approximately 50 times that of treatment with Avastin. Costs 
can effectively make certain drugs unavailable to patients. In 
South Africa the price difference between drugs of comparable 
efficacy is significant in the choice of drug.1,3,6
Avastin is produced in 100 mg vials. For colorectal cancer 
a dosage of 5 - 10 mg per kg body weight every 14 days is 
prescribed. A person weighing 60 kg would therefore receive 
3 - 6 vials every 14 days. The commonly used dose for the 
treatment of AMD is 1.25 mg per injection. It can be injected 
into an eye repeatedly, at intervals of 1 month to 6 weeks, or as 
clinically indicated. Most patients need only 2 or 3 injections.22 
The larger Avastin ampoule is often fractionated for use in 
multiple eyes, and the cost to the ophthalmologist per injection 
then varies between US$17 and US$50. The cost of a single vial 
of Lucentis (0.5 mg in 0.05 ml) is US$1 950.6 The view has been 
expressed that Avastin might well be safer than the multiple 
injections used with Lucentis or Macugen. Injections carry the 
inherent risk of causing glaucoma, endophthalmitis, damage to 
the structures of the eye and bleeding.6,23
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Genentech raised concerns about the compounding of 
Avastin into smaller doses for intra-ocular use, as it was 
unapproved and patients could accordingly be at a higher 
risk, and notified physicians that it would not sell Avastin to 
compounding pharmacies. The ophthalmic community, led by 
the American Academy of Ophthalmology and the American 
Society of Retinal Specialists, reached an agreement with 
Genentech whereby the company would provide Avastin to 
retinal surgeons, who could get compounding pharmacies to 
‘cut’ the dose to the appropriate ophthalmic dosage.24
 The need for large randomised control trials is obvious. 
Trials comparing the efficacy, safety and optimal dosing of 
Avastin and Lucentis  are underway in the UK25 and the USA.26 
Conclusion and recommendations
Ophthalmologists have access to a reportedly effective and 
safe drug to treat a serious disease, but without the backing 
of randomised controlled trials, without the blessing of the 
manufacturer of the drug, and without registration for intra-
ocular use by the MCC. In the event of a complication, would 
the ophthalmologist have a legal leg to stand on? On the other 
hand, if a patient lost sight due to AMD, could negligence by 
the ophthalmologist who had access to Avastin be suggested?      
Off-label use of medication carries a higher risk for the 
patient and the practitioner than its registered use, so 
extra care should be taken. The off-label use of Avastin has 
passed the innovative or experimental stages, and its use 
by ophthalmologists is widespread in South Africa and 
elsewhere in the world.  It has been used regularly and openly 
over a long time, with a high degree of success and without 
undue harm to patients. The off-label use of Avastin for 
AMD and macular oedema is also well documented.3,6,7,27-29 
The off-label use of Avastin cannot therefore be branded as 
careless, imprudent or unprofessional. It is submitted that 
an ophthalmologist who omits to inform a patient of the 
availability of Avastin for this form of treatment may be found 
to be negligent. 
The protocols developed by the South African Vitreoretinal 
Society and endorsed by the Ophthalmological Society of 
South Africa for administering Avastin and other intra-ocular 
medication intravitreally cover aspects such as informed 
consent, possible complications such as endophthalmitis, the 
off-label use of the drug, and pre-injection management.3 If it 
is affordable, patients should be given the option of choosing 
Lucentis. These protocols should be strictly adhered to.
From a legal/ethical point of view, patients suffering from 
AMD and macular oedema who cannot afford the registered 
product should be given the opportunity to be treated with the 
off-label product, especially to prevent functional blindness. 
Funders should cover the costs associated with the off-label 
use of Avastin. Owing to financial pressures many funders 
in the UK commission ‘Avastin only’ services for these 
eye conditions. To act in the best interests of their patients, 
ophthalmologists must be empowered by having this cost-
effective alternative medication available.
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